一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括zanubrutinib；bendamustine；rituximab，当前状态为研究进行中，已停止招募。登记地点显示中国北京、福州、泉州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
zanubrutinib；bendamustine；rituximab · III 期
登记条件中文摘要
年龄范围：60岁及以上
登记的基本范围为不限性别，年龄60岁及以上；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Peoples Hospital · 北京
- Beijing Friendship Hospital, Capital Medical University · 北京
- Fujian Medical University Union Hospital · 福州
- Quanzhou First Affliated Hospital of Fujian Medical University · 泉州
- Sun Yat Sen University Cancer Center · 广州
- Guangdong Provincial Peoples Hospital · 广州
- Nanfang Hospital of Southern Medical University · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Henan Cancer Hospital · 郑州
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology · 武汉
- Hunan Cancer Hospital · 长沙
- Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School · 南京
- Jiangsu Province Hospital · 南京
- The Affiliated Hospital of Xuzhou Medical University · 徐州
- The First Affiliated Hospital of Nanchang University Branch Donghu · 南昌
- Jilin Cancer Hospital · 长春
- The First Hospital of Jilin University · 长春
- Shengjing Hospital of China Medical University · 沈阳
- Fudan University Shanghai Cancer Center · 上海
- Shanghai East Hospital · 上海
- West China Hospital, Sichuan University · 成都
- Institute of Hematology and Hospital of Blood Disease · 天津
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Affiliated Cancer Hospital of Xinjiang Medical University · 乌鲁木齐
- The First Affiliated Hospital, Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital) · 宁波
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. ≥70 years of age at the time of informed consent, OR ≥60 and \<70 years of age with comorbidities precluding autologous stem cell transplantation
- 2. Histologically confirmed diagnosis of MCL
- 3. No prior systemic treatments for MCL
- 4. Measurable disease by CT/MRI
- 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- 6. Adequate marrow and organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04002297；登记信息更新于 2026-09-30；本站同步于 2026-10-08。